Comparative effectiveness of surgery and radiotherapy for survival of patients with clinically localized prostate cancer: A population-based coarsened exact matching retrospective cohort study.

The objective of the current study was to compare the survival outcomes of patients with clinically localized prostate cancer and in elderly and young patients receiving surgery and radiotherapy. The survival outcomes of patients with localized prostate cancer (age at diagnosis ≤79 years, clinical T1-3) initially treated with surgery or radiotherapy were retrospectively analyzed. Data were collected from the population-based cancer registry of the Kanagawa Prefecture, Japan. A 1:1 coarsened exact matching of age at diagnosis, clinical T stage and cancer differentiation was performed between the two treatment groups. Patients were also categorized into two subgroups by age using a cutoff of 70 years for analysis. The cohort comprised 4,810 patients aged 50-79 years. No significant difference in cancer-specific survival (CSS) was observed between the two groups (P=0.612). However, the surgery group had significantly better overall survival (OS; P=0.004). When stratified for age, similar tendencies were observed in the elderly group (aged 70-79 years; CSS, P=0.961 and OS, P=0.007). No significant difference in either CSS or OS was identified in the younger group (P=0.550 and P=0.408, respectively). Intrinsic deaths were more likely to occur in elderly patients treated with radiotherapy than those undergoing surgery (69.3 vs. 78.2%; P=0.128). The results indicated that surgery provided significantly better OS than radiotherapy, particularly among the elderly. However, no signi...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

AbstractPurposeTestosterone replacement therapy (TRT) remains controversial in men with treated prostate cancer. We assessed its safety and functional impacts in patients after definitive surgical treatment with robotic-assisted radical prostatectomy (RARP).MethodsWe performed a retrospective analysis of 1303 patients who underwent RARP during the years 2006 –2019. We identified men with symptoms of andropause and low serum testosterone who received TRT post-RARP; then we divided the cohort into two groups accordingly for comparison. Biochemical recurrence (BCR) was the primary endpoint. Secondary endpoints included ...
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Kojiro Tashiro, Fumihiko Urabe, Daisuke Ito, Mahito Atsuta, Hiroshi Sasaki, Shin Egawa
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
This study included men who had undergone radical prostatectomy with neoadjuvant hormonal therapy between 2003 and 2016. We evaluated the association between clinicopathological factors and smoking status as well as the prognostic significance of smoking status in biochemical recurrence. The patients' backgrounds were comparable between smokers and nonsmokers. Smoking status were identified as significant risk factors of biochemical recurrence. Smoking was a risk factor of biochemical recurrence, suggesting that smoking may promote cancer recurrence after surgical treatment combined with hormonal therapy. PMID: 3301614...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
(Society of Nuclear Medicine and Molecular Imaging) A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of The Journal of Nuclear Medicine. The feasibility study showed that 68Ga-PSMA CLI can image the entire excised prostate specimen's surface to detect prostate cancer tissue at the resection margin.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Optimal management strategies for clinically localised prostate cancer are debated. Using median 10-year data from the largest randomised controlled trial to date (ProtecT), the lifetime cost-effectiveness of ...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
CONCLUSIONS: Among multiple abbreviated mpMRI-derived protocols, cesMRI was the one equaling mpMRI in terms of csPCa detection and minimizing PI-RADSv2 category 3 assignments. PMID: 33016030 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
In this study, we evaluated prostate multiparametric MRI (mpMRI) before and after neoadjuvant enzalutamide plus ADT. EXPERIMENTAL DESIGN: Men with localized intermediate- or high-risk prostate cancer underwent a baseline mpMRI and mpMRI-targeted biopsy followed by a second mpMRI after 6 months of enzalutamide and ADT prior to RP. Specimens were sectioned in the same plane as mpMRI using patient-specific 3D-printed molds to permit mpMRI-targeted biopsies to be compared to the same lesion from the RP. Specimens were analyzed for imaging and histologic correlates of response. RESULTS: Of 39 patients enrolled, 36 com...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
MONDAY, Oct. 5, 2020 -- Adjuvant radiotherapy does not improve event-free survival in men with localized or locally advanced prostate cancer treated with radical prostatectomy, according to a review and meta-analysis published online Sept. 28 in The...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 3 October 2020Source: European UrologyAuthor(s): Romain Diamand, Guillaume Ploussard, Mathieu Roumiguié, Marco Oderda, Daniel Benamran, Gaelle Fiard, Thierry Quackels, Grégoire Assenmacher, Giuseppe Simone, Julien Van Damme, Bernard Malavaud, Christophe Iselin, Jean-Luc Descotes, Jean-Baptiste Roche, Alexandre Peltier, Thierry Roumeguère, Simone Albisinni
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 3 October 2020Source: European UrologyAuthor(s): Carlo A. Bravi, Francesco Montorsi, Alberto Briganti
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Japan Health | Prostate Cancer | Prostatectomy | Study